


RECEIVED

AUG 18 2003

TECH CENTER 1600/2900



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.
ELI LILLY AND COMPANY

By [Signature]

Date 8-1-03

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Charles Jack Fisher et al.)
Serial No. : 09/998,393)
Filed : November 2, 2001) Group Art Unit:
For : METHODS FOR TREATING SEPSIS) 1654
Docket No. : X-12444A) Examiner:
J. RUSSEL

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Identification of Person Making This Disclaimer

I, Thomas E. LaGrandeur, am employed by Eli Lilly and Company, and I am an agent of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

Identity of Assignee

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285

08/15/2003 MMKONEN 00000095 050840 09998393

01 FC:1814

110.00 DA

Recordal of Assignment in PTO

The assignment was recorded on October 15, 1999,
Reel 010303, Frame 0955.

Extent of Interest

The extent of Eli Lilly and Company's interest is
in the whole of this invention.

Disclaimer

I hereby disclaim the terminal part of any patent
granted on this application, which would extend beyond the
expiration date of:

United States Patent No. 6,156,734 and hereby
agree that any patent granted on this application shall be
enforceable only for and during such period that the legal
title to the patent shall be the same as the legal title to
United States Patent No. 6,156,734.

I do not disclaim any terminal part of any patent
granted on this application prior to the expiration date of
the full statutory term of United States Patent No.
6,156,734 in the event that it later: expires for failure
to pay a maintenance fee, is held unenforceable, is found
invalid, is statutorily disclaimed in whole or terminally
disclaimed under 37 C.F.R. 1.321, has all claims cancelled
by a reexamination certificate, or is otherwise terminated
prior to expiration of its full statutory term other than as
presently shortened by any terminal disclaimer.

Fee Payment


Please charge \$110.00, the fee set forth in
37 C.F.R. 1.20(d), and charge any additional fees which may
be required by this or any other related paper, or credit

Serial No. 09/998,393

any overpayment to Deposit Account No. 05-0840, in the name of Eli Lilly and Company. Two copies of this disclaimer are enclosed.

ELI LILLY AND COMPANY

By:


Thomas E. LaGrandeur
Agent for Applicants
Registration No. 51,026
Phone: 317-651-1527

Eli Lilly and Company
Patent Division/TEL
Lilly Corporate Center
Indianapolis, Indiana 46285

August 11, 2003